Morgan Stanley lowered the firm’s price target on enGene (ENGN) to $19 from $34 and keeps an Overweight rating on the shares after the company reported Q2 results and provided an update on the LEGEND study of detalimogene in non-muscle invasive bladder cancer. The firm has tempered peak detalimogene share within its model as it awaits further clarity on likely commercial uptake of competing programs, the analyst tells investors.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENGN:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue